• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

    74.83 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 22, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 10
    Open 74.83
    Bid (Size) 72.00 (100)
    Ask (Size) 74.83 (100)
    Prev. Close 74.83
    Today's Range 74.83 - 74.83
    52wk Range 28.46 - 86.74
    Shares Outstanding 141,797,854
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Ionis (IONS) Q4 2025 Earnings Transcript ↗
    Ionis (IONS) Q4 2025 Earnings Transcript 
    Via The Motley Fool
    News headline image
    Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire

    Performance

    YTD
    -6.1%
    -6.1%
    1 Month
    +5.7%
    +5.7%
    3 Month
    -5.8%
    -5.8%
    6 Month
    +4.7%
    +4.7%
    1 Year
    +157.8%
    +157.8%

    More News

    Read More
    News headline image
    Ionis to hold first quarter 2026 financial results webcast
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    Ionis Pharmaceuticals (NASDAQ:IONS) Shows High Technical and Setup Ratings for Potential Breakout ↗
    Via Chartmill
    IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Shows High-Quality Technical Breakout Setup ↗
    Via Chartmill
    News headline image
    Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss
    Via MarketMinute
    News headline image
    When Insider Selling Is a Good Thing: 2 Stocks to Watch ↗
    Via MarketBeat
    News headline image
    Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026 ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position ↗
    Via The Motley Fool
    News headline image
    Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy? ↗
    Via The Motley Fool
    News headline image
    Vertex Pharmaceuticals Surges 8.3% as Renal Breakthrough Sparks Market Rally
    Via MarketMinute
    Topics Stocks
    News headline image
    Ionis announces changes to Board of Directors
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis to present at upcoming investor conferences
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Ionis updates time for fourth quarter and full year 2025 financial results webcast
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance
    Via Finterra
    Topics Economy Intellectual Property
    News headline image
    Ionis to hold fourth quarter and full year 2025 financial results webcast
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
    From Biogen Inc.
    Via GlobeNewswire
    News headline image
    What a $20 Million Bet on a Stock Down 3% Signals for Investors ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Autoliv Stock Is Up 32% in a Year, But One Fund Just Cut $3.8 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance Supply Chain
    News headline image
    DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
    From Ionis Pharmaceuticals, Inc.
    Via Business Wire
    News headline image
    Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
    From Biogen Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Ionis Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Ionis Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Ionis Pharmaceuticals, Inc. - Common Stock trade on?
    Ionis Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Ionis Pharmaceuticals, Inc. - Common Stock is IONS on the Nasdaq Stock Market
    What is the current price of Ionis Pharmaceuticals, Inc. - Common Stock?
    The current price of Ionis Pharmaceuticals, Inc. - Common Stock is 74.83
    When was Ionis Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Ionis Pharmaceuticals, Inc. - Common Stock was at 04/22/26 04:00 PM ET
    What is the market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Ionis Pharmaceuticals, Inc. - Common Stock is 10.61B
    How many shares of Ionis Pharmaceuticals, Inc. - Common Stock are outstanding?
    Ionis Pharmaceuticals, Inc. - Common Stock has 11B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.